| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Voltage-Gated Sodium Channel (NaV)
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Benzocaine (non-deuterated) shares a common receptor with all other local anesthetics in the voltage-gated Na+ channel, with an IC50 of 0.8 mM tested with a potential of +30 mV. The ethyl-d5 version is used for studying metabolic pathways and degradation processes of benzocaine as a tracer. The compound acts as a co-receptor on voltage-gated Na+ channels with the same IC50. |
| ln Vivo |
No specific in vivo data for the labeled compound. The non-deuterated benzocaine is a topical local anesthetic used to relieve pain and itching from minor burns, sunburn, insect bites, and other skin irritations. It is also used as a topical anesthetic for procedures such as endoscopy or catheter insertion. The ethyl-d5 version is not used in vivo but rather as an analytical internal standard.
|
| Enzyme Assay |
For biochemical assays, the non-deuterated benzocaine is used. Radioligand binding assays with [3H]batrachotoxin or [3H]saxitoxin on voltage-gated sodium channels from rat brain synaptosomes can be used. Alternatively, whole-cell patch-clamp electrophysiology on HEK293 cells expressing NaV channels (e.g., NaV1.7) is performed. Cells are held at hyperpolarized potentials to ensure channels are in the resting state, and benzocaine (0.1-10 mM) is applied. IC50 values are determined.
|
| Cell Assay |
For cellular assays, HEK293 cells expressing human NaV1.7 channels are cultured in DMEM with 10% FBS. Whole-cell patch-clamp recordings are performed. The external solution contains NaCl, KCl, CaCl2, MgCl2, HEPES, and glucose. The internal solution contains CsF, CsCl, and EGTA. Cells are held at -120 mV and stepped to -10 mV. Benzocaine (0.1-10 mM) is applied, and the reduction in peak sodium current is measured, yielding an IC50 of ~0.8 mM. The deuterated form is not used in these assays except as an internal standard.
|
| Animal Protocol |
No specific in vivo animal study for Benzocaine-(ethyl-d5). For the unlabeled benzocaine, in vivo anesthetic activity is assessed by the guinea pig intradermal wheal test or rat tail-flick test. Benzocaine (5-20%) is applied topically, and the degree and duration of sensory blockade are measured by response to pinprick. The deuterated form is not used in animal efficacy studies; it is an analytical standard.
|
| ADME/Pharmacokinetics |
Benzocaine-(ethyl-d5) is not administered in vivo; it is an analytical internal standard. The unlabeled benzocaine is rapidly absorbed through mucous membranes but poorly absorbed through intact skin. Onset of action is rapid (30-60 seconds). Duration is 15-30 minutes. It is metabolized in the plasma by pseudocholinesterases to p-aminobenzoic acid (PABA). Half-life is short. The ethyl-d5 version would have identical PK if administered, but it is used as a tracer.
|
| Toxicity/Toxicokinetics |
Benzocaine-(ethyl-d5) is for research use only; not for human consumption. Unlabeled benzocaine has low systemic toxicity when used topically. Overuse can cause methemoglobinemia, especially in infants and young children. Allergic reactions (contact dermatitis) can occur, particularly in individuals sensitive to PABA and its derivatives. The deuteration does not alter the toxicological profile, but the compound is used only at trace levels in analytical assays.
|
| References |
|
| Additional Infomation |
Benzocaine-(ethyl-d5) (CAS: 1219803-76-5) is a stable isotope-labeled compound used as an internal standard for the quantification of benzocaine in biological samples by LC-MS or GC-MS. This is useful for analyzing benzocaine levels in drug formulations, environmental samples, or in pharmacokinetic studies where benzocaine is used. Synonyms: Ethyl-d5 4-aminobenzoate. Molecular weight: 170.22. For research use only. References: Deuterated standards catalog.
|
| Molecular Formula |
C9H11NO2
|
|---|---|
| Molecular Weight |
170.219950914383
|
| Exact Mass |
170.11
|
| CAS # |
1219803-76-5
|
| Related CAS # |
Benzocaine;94-09-7
|
| PubChem CID |
131869360
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
12
|
| Complexity |
151
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(OC([2H])([2H])C([2H])([2H])[2H])(=O)C1=CC=C(N)C=C1
|
| InChi Key |
BLFLLBZGZJTVJG-ZBJDZAJPSA-N
|
| InChi Code |
InChI=1S/C9H11NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6H,2,10H2,1H3/i1D3,2D2
|
| Chemical Name |
1,1,2,2,2-pentadeuterioethyl 4-aminobenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8748 mL | 29.3738 mL | 58.7475 mL | |
| 5 mM | 1.1750 mL | 5.8748 mL | 11.7495 mL | |
| 10 mM | 0.5875 mL | 2.9374 mL | 5.8748 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
